### Lampiran 1.



ASLI

#### SURAT KETERANGAN BUKTI BEBAS PLAGIASI

Naskah tugas akhir / skripsi / karya tulis / tesis\*) yang diserahkan atas :

N a m a : Muhammad As'aduddin

NIM : 20191660002

Fakultas/Jurusan : Fakultas Ilmu Kesehatan / S1 Keperawatan

Alamat : Dukuh Kupang Gg lebar 16/12 RT 04 RW 07 - Surabaya Judul : Status Diabetes Mellitus Terhadap Tingkat Keparahan Penyakit

COVID—19 (Literatur Review)

telah diserahkan dan memenuhi kriteria batas maksimal yang sudah ditentukan.

Petugas perpustakaan

Putri Rokhmawati

Surabaya, 05 Februari 2021

Mahasiswa,

Muhammad As'aduddin

\*) DILARANG KERAS MENYEBARLUASKAN FORM INI



#### PERPUSTAKAAN UNIVERSITAS MUHAMMADIYAH SURABAYA

**ARSIP** 

### SURAT KETERANGAN BUKTI BEBAS PLAGIASI

Naskah tugas akhir / skripsi / karya tulis / tesis\*) yang diserahkan atas :

N a m a : Muhammad As'aduddin

NIM : 20191660002

Fakultas/Jurusan : Fakultas Ilmu Kesehatan / S1 Keperawatan

Alamat : Dukuh Kupang Gg lebar 16/12 RT 04 RW 07 - Surabaya
Judul : Status Diabetes Mellitus Terhadap Tingkat Keparahan Penyakit

COVID-19 (Literatur Review)

telah diserahkan dan memenuhi kriteria batas maksimal yang sudah ditentukan.

Dra, Mas ulah, M.A

Petugas perpustakaan

Putri Rokhmawati


Surabaya, 05 Februari 2021

Mahasiswa,


All As'aduddin

\*) DILARANG KERAS MENYEBARLUASKAN FORM INI


### Lampiran 2.




Hasil penelusuran database NCBI PubMed : No Filter




Hasil penelusuran database NCBI PubMed: Filter with Abstract and Full Text




Hasil penelusuran database NCBI PubMed: Filter dengan karakteristik inklusi



Hasil penelusuran database Proquest : No Filter



Hasil penelusuran database Proquest: Filter with Abstract and Full Text



Hasil penelusuran database Proquest : Filter dengan karakteristik inklusi



# PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta- analysis, or both.	
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	
INTRODUCTIO	N		
Rationale	3	Describe the rationale for the review in the context of what is already known.	
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	

Section/topic	#	Checklist item	Reported on page #
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	
DISCUSSION			
Summary of evidence			

Section/topic	#	Checklist item	Reported on page #
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit:  $\underline{www.prisma-statement.org}.$ 

### Lampiran 4.

# Libraries PIKES PEAK COMMUNITY COLLEGE

Centennial Campus Library: 5675 S. Academy Blvd., Room A201 Circulation: 719.502.2400 • Reference: 719.502.3410

Rampart Range Campus Library: 11195 Highway 83, Room N201 Circulation: 719.502.2440 • Reference: 719.502.3430

askalibrarian@ppcc.edu • Text/SMS: 719.582.5598

CRAAP Test SCORE CARD for Evaluating Sources		
Use the questions below to help you evaluate your sources. This can be used		
for print and online sources. Answer the questions then score each section		
from 1 - 10 (1 = unreliable, 10 = excellent). Add up the scores to help you decide whether you should use that particular source for your assignment.		
decide whether you should use that particular source for your assignment.		
Currency	YES	NO
When was the information published/posted?	_	_
Has the information been updated?	Ч	Щ
Does the information need to be current for your needs?	U	u
Relevance		Į
Does the information you found match the topic for your assignment?		Ц
Have you looked at other sources before selecting this one?	П	Ц
Are your questions answered by this source?		<u>u</u>
Authority		
Who is the author or publisher of the information?		
Can you find and verify the author or publisher's credentials?		
Does the URL help you determine the source? (.edu; .com; .gov)		
Accuracy		
Can you verify this information in another source?		
Did the author back up his/her statements with evidence and list sources?		
Are there lots of spelling or grammar errors or typos?		
Purpose		
What is the purpose of the information? Does it aim to teach, entertain, sell, etc.?		
Is the information unbiased; does the author or publisher seem impartial?		
Are there political, religious, cultural or other biases present?		
Scoring: TOTAL SCORE  45-50 Excellent • 40-44 Good • 35-39 Average 30-34 May or may not be Acceptable		
Below 30 Not an acceptable source		

The Score Card is adapted from the CRAAP test created at the Meriam Library at California State University Chico.

## Lampiran 5.

# Hasil skoring CRAAP Test

No	Judul Artikel	С	R	Α	Α	Р	Total
1	Mortality rate and predictors of mortality in hospitalized COVID-19 patients with diabetes	10	8	8	10	10	46
2	COVID-19: Impact of obesity and diabetes on disease severity	10	10	10	8	10	48
3	Risk factors for disease progression in COVID-19 patients	10	8	10	10	10	48
4	Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: The Pisa COVID-19 study	10	8	8	10	10	46
5	Diabetes is a risk factor for the progression and prognosis of COVID-19	10	10	10	8	10	48
6	Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease	10	8	10	10	10	48
7	Impaired glucose metabolism in patients with diabetes, prediabetes and obesity is associated with severe COVID-19	10	10	10	8	10	48
8	Clinical characteristics of 28 patients with diabetes and COVID-19 in Wuhan, China	10	8	10	10	10	48
9	The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID-19	10	10	10	8	10	48
10	Clinical characteristics and outcomes of patients with severe COVID-19 with diabetes	10	10	10	10	10	50
11	The Clinical Characteristics and Outcomes of Diabetes Mellitus and Secondary Hyperglycaemia Patients with Coronavirus Disease 2019: a Single-center, Retrospective, Observational Study in Wuhan	10	10	10	8	10	48